

Claim 12, line 2, delete "as defined in claim 3".

Claim 13, line 1, delete "or 12".

Claim 14, line 1, delete "or 12".

Claim 15, lines 1 and 2, delete "any one of claims 5 to 10 or a vector of any one of claims 11 to 14", and insert --claim 5--.

Claim 16, lines 1 and 2, delete ", such as a mammalian cell".

17. (Amended) A composition comprising a polypeptide of [any one of claims 1 to 3] claim 1, an analogue [of claim 4] thereof, a polynucleotide [of any one of claims 5 to 10], a vector [of any one of claims 11 to 14], comprising said polypeptide or a host cell [of claim 15 or 16] comprising said polypeptide or a combination of two or more of these different compounds.

19. (Amended) [Use of a polypeptide of any one of claims 1 to 3, of an analogue of claim 4, of a polynucleotide of any one of claims 5 to 10, of a vector of any one of claims 11 to 14, of a host cell of claim 15 or 16 or of a composition of claim 17 for the preparation of a medicament] A method for effecting a CTL response in a subject comprising a polypeptide according to claim 1.

Claim 20, line 1, delete "any one of claims 1 to 3" and insert --claim 1--.

21. (Amended) A vaccine comprising a polypeptide of [any one of claims 1 to 3],  
an analogue [of claim 4] thereof, a polynucleotide [of any one of claims 5 to 10], a vector  
[of any one of claims 11 to 14] or a host cell [of claim 15 or 16], which vaccine is capable  
of stimulating a MHC class I restricted T cell response directed to an epitope as contained  
in a polypeptide of [any one of claims 1 to 3] claim 1.

Claim 23, lines 1 and 2, delete "any one of claims 1 to 3", and insert --claim 1--.

27. (Amended) The product of claim 26 which product comprises (a) an HLA  
molecule, or a fragment thereof, comprising a polypeptide of [any one of claims 1 to 3]  
claim 1 or an analogue [of claim 4] thereof in its peptide binding groove, or (b) an analogue  
of (a) which is capable of inhibiting the binding of (a) to a T cell receptor [of claim 23].

Claim 28, line 1, delete "or 27".

Claim 28, line 2, delete "of claim 23".

Claim 29, line 1, delete "or 27".

30. (Amended) A method of identifying a MHC class I restricted T cell response,  
said method comprising contacting a population of cells comprising MHC class I restricted  
T cells with:

the polypeptide of [any one of claims 1 to 3] claim 1 or with [the] an analogue [of claim 4] thereof under conditions suitable for the presentation of the polypeptide or analogue to the T cells,

or

a product [of claim 26 or 27 or cells of claim 29] that selectively binds a T cell receptor;

and

determining whether the CD8 T cells recognize the polypeptide, analogue, the product or the cell, recognition by the T cells indicating the presence of a MHC class I restricted T cell response.

Claim 33, line 3, delete "any one of claims 1 to 3", and insert claim 1.

Claim 35, lines 4-6, delete "any one of claims 1 to 3 with the analogue of claim 4 under conditions in which the polypeptide or the analogue are presented to T cells in the population, or with a product of claim 26 or 27 or with a cell of claim 29", and insert claim 1.

Claim 36, lines 1 and 2, delete "product of claim 26 or 27, a cell of claim 28, the T cell of claim 24 or 25, or a".

Claim 37, line 1, delete "for carrying out a method of any one of claims 30 to 35".

Claim 37, lines 2-3, delete "any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a composition of claim 17 and/or a product of claim 26 or 27], and insert claim 1 and adjuvants.